Cover Image
市場調查報告書

Gliquidone的中國市場

Investigation Report on China Gliquidone Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 335238
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Gliquidone的中國市場 Investigation Report on China Gliquidone Market, 2010-2019
出版日期: 2015年07月10日 內容資訊: 英文 30 Pages
簡介

2014年的中國Gliquidone市場上,Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd以銷售額為準獲得97%的巨大佔有率,殘餘的僅僅3%的佔有率由TIPR Pharmaceutical Responsible Co., Ltd,Jiangsu Vanguard Pharmaceutical Co., Ltd,Jilin Jinheng Pharmaceutical Co., Ltd,Shijiazhuang Yiling Pharmaceutical Co., Ltd的企業分享。

本報告提供中國的Gliquidone的市場相關調查、Gliquidone的功效、效果、中國市場中專利及核准狀況、銷售額、銷售量的變化與預測、價格趨勢、主要製造商與市場佔有率、競爭環境與其展望、主要製造商簡介等彙整資料。

第1章 Gliquidone的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國的Gliquidone的市場簡介

  • 專利情形
  • 主要製藥公司
  • 市場規模

第3章 中國的Gliquidone銷售情形

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國的Gliquidone的主要製藥公司市場佔有率

  • 銷售額為基礎的市場佔有率
  • 銷售量為基礎的市場佔有率

第5章 中國的Gliquidone的劑型的相關調查

  • 各劑型的市場佔有率:銷售額為基礎
  • 各劑型的市場佔有率:銷售量為基礎

第6章 中國的醫院的Gliquidone的標準價格

  • Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd (商品名:Glurenorm)
  • TIPR Pharmaceutical Responsible Co., Ltd
  • Jiangsu Vanguard Pharmaceutical Co., Ltd
  • Jilin Jinheng Pharmaceutical Co., Ltd
  • Shijiazhuang Yiling Pharmaceutical Co., Ltd

第7章 中國市場中Gliquidone的主要製藥公司

  • Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd
  • TIPR Pharmaceutical Responsible Co., Ltd
  • Jiangsu Vanguard Pharmaceutical Co., Ltd

第8章 中國的Gliquidone的市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1507264

According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.

As one of the earliest oral antidiabetic drugs, sulfonylurea is common to patients with insulin hyposecretion. By stimulating insulin secretion, sulfonylurea is able to reduce blood glucose. According to the length of action, sulfonylurea can be categorized into short-acting, medium-acting and long-acting preparations. And glibenclamide, gliquidone, gliclazide and glimepiride are the common drugs in the class of sulfonylurea.

Developed by Boehringer-Ingelheim, gliquidone first came into the German market in 1975 under the trade name of Glurenorm. As the main metabolite of gliquidone is eliminated from body with bile and only 5% is excreted renally, i.e. hardly influenced by glomerular filtration rate (GFR), drug metabolism can ease kidney's burden and therefore more suitable for patients with damaged renal function. Gliguidone is with good tolerance and few side effects for common patients and few, if any, patients will have skin allergy, gastrointestinal discomfort and sensation of vertigo. If guiguidone alone doesn't work, metformin could be added in the treatment.

As gliquidone is expelled from the body with bile after being metabolized by CYP3A4 enzyme system in the liver and only 6% of it is excreted through kidney, it is more suitable for patients with kidney disorders.

In 1990, gliquidone co-produced by Boehringer-Ingelheim and Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd entered China under the trade name of Glurenorm. And in 1997, gliquidone developed by TIPR Pharmaceutical Responsible Co., Ltd came into the market under the trade name of Jieshi. Apart from the above-mentioned two products, other products are also available in the Chinese market.

According to CRI's market survey, in 2014, Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd took up a market share of about 97% for sales value in China while other companies like TIPR Pharmaceutical Responsible Co., Ltd, Jiangsu Vanguard Pharmaceutical Co., Ltd and Jilin Jinheng Pharmaceutical Co., Ltd and Shijiazhuang Yiling Pharmaceutical Co., Ltd shared the rest market share. The annual sales value of gliquidone in sample hospitals stays at CNY 40 million in recent years.

Readers can get at least the following information through this report:

  • market size of gliquidone in China
  • major manufacturers of gliquidone for Chinese market and their market share
  • retail price of gliquidone in Chinese market
  • market outlook of gliquidone in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-diabetic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Gliquidone

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Gliquidone in China

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Gliquidone in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Gliquidone in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Gliquidone in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Gliquidone in Chinese Hospitals in 2014

  • 6.1. Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd (Trade Name: Glurenorm)
  • 6.2. TIPR Pharmaceutical Responsible Co., Ltd
  • 6.3. Jiangsu Vanguard Pharmaceutical Co., Ltd
  • 6.4. Jilin Jinheng Pharmaceutical Co., Ltd
  • 6.5. Shijiazhuang Yiling Pharmaceutical Co., Ltd

7. Major Manufacturers of Gliquidone in Chinese Market, 2010-2014

  • 7.1. Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd
  • 7.2. TIPR Pharmaceutical Responsible Co., Ltd
  • 7.3. Jiangsu Vanguard Pharmaceutical Co., Ltd

8. Market Outlook of Gliquidone in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Registration Information of Gliquidone in China
  • Chart Approval Status of Gliquidone in China
  • Chart Sales Status of Gliquidone in China, 2010-2014
  • Chart Sales Value of Gliquidone in China, 2010-2014
  • Chart Sales Value of Gliquidone by Regions in China, 2010-2014
  • Chart Sales Value of Gliquidone Tablets in China, 2010-2014
  • Chart Market Share of Major Manufacturers of Gliquidone for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Gliquidone Made by Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd, 2010-2014
  • Chart Sales Value and Market Share of Gliquidone Made by TIPR Pharmaceutical Responsible Co., Ltd, 2010-2014
  • Chart Sales Value and Market Share of Gliquidone Made by Jiangsu Vanguard Pharmaceutical Co., Ltd, 2010-2014
  • Chart Price of Gliquidone Made by Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Gliquidone Made by TIPR Pharmaceutical Responsible Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Gliquidone Made by Jiangsu Vanguard Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Gliquidone Made by Jilin Jinheng Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Gliquidone Made by Shijiazhuang Yiling Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top